BioCentury
ARTICLE | Company News

Novartis grants Magenta rights to MGTA-456

May 5, 2017 8:00 PM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) granted Magenta Therapeutics Inc. (Cambridge, Mass.) rights to MGTA-456 (formerly HSC835) in selected applications, including immune and blood diseases.

The product comprises umbilical cord blood hematopoietic stem cells that have been expanded using an aryl hydrocarbon receptor antagonist. In patients undergoing transplantation, the product is intended to shorten patient recovery times by increasing numbers of blood-forming stem cells...

BCIQ Company Profiles

Novartis AG